Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trodelvy
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Teva snares up to $150M in Abingworth funding for inhaler program
Apr 1, 2024 10:51am
Gilead secures $210M from Abingworth to fund Trodelvy trials
Feb 29, 2024 10:31am
Gilead's at 'just the beginning' of cell therapy movement: exec
Feb 7, 2024 2:08pm
Gilead's Trodelvy fails to extend survival in lung cancer study
Jan 22, 2024 9:59am
Cancer 'steals possibilities,' but Gilead is 'taking it back'
Nov 16, 2023 8:05am